# Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

> **NCT06393335** · EARLY_PHASE1 · UNKNOWN · sponsor: **The Children's Hospital of Zhejiang University School of Medicine** · enrollment: 36 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Metabolically Armed CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT06393335
- **Lead sponsor:** The Children's Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-15
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393335, "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06393335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*